Abstract 2753: Observation of Long-Term Efficacy and Safety of an ATR12181 Vaccine Against Hypertension in SHR
Background: We have established previously that vaccine-ATR12181 could effectively reduce blood pressure (BP) and ameliorated the remodeling of target organs of SHR in 5 months. Long-term efficacy and safety are necessary for the vaccine against hypertension.
Methods and results: We performed a 16 months long-term observation of the vaccine. Male SHR of 6 weeks age were immunized against the peptide from rat AT1A receptor by repeated subcutaneous injections of peptide-tetanus-toxoid complex in combination with Freund’s adjuvant (ATR, n=6). SHR in control group were received 0.9% sodium chloride (Con, n=6). As expect, SHR in ATR group had lower systolic BP than Con group (16th month, ATR, 180 ± 6mmHg; Con, 197 ± 4mmHg, P<0.01). Left ventricular (LV) hypertrophy was significantly attenuated, as evidenced by decreased the heart mass to body mass ratio (ATR, 2.5 ± 0.1 mg/g; Con, 4.2 ± 0.2 mg/g, P<0.01). Vaccine-ATR12181 significantly reduced LV fibrosis (in Fig. 1⇓). And damages of glomerulus and interstitial fibrosis in kidneys were attenuated in ATR group compared with Con group (in Fig. 1⇓). In addition, wall-to-lumen ratio of mesenteric arteries in ATR group significantly decreased compared with Con group (in Fig. 1⇓). Morphological examinations of important organs including heart, kidneys, lungs, brain and liver did not find any signs of autoimmune damages in ATR group and confirmed safety of the vaccine.
Conclusion: The results indicated that long-term vaccination with the vaccine-ATR12181 could effectively reduce BP and reverse remodeling of target organs in SHR, meanwhile vaccine-ATR12181 was safe during the long-term antihypertensive therapy.